NCT05133076 2025-06-26
OIC1
BioGaia Pharma AB
Phase 2 Completed
Clinical Trials
9 trialsNCT03638440 2024-06-17
NACASY
Kyowa Kirin Co., Ltd.
Completed
NCT02270983 2019-04-08
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Forest Laboratories
Phase 2 Completed
NCT01395524 2017-02-23
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT00135577 2015-09-02
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT01323790 2015-06-02
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01309841 2015-06-01
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01336205 2014-10-20
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT00984334 2013-12-27
Naloxone SR Capsules in Patients With Opioid Induced Constipation
S.L.A. Pharma AG
Phase 2 Completed